Executive Summary (TL;DR): Healthcare & biotech, fintech, and food & agriculture account for roughly 40% of the 431 VC-backed startup shutdowns CB Insights tracked, each failing for a structurally different reason: clinical risk, funding-cycle risk, and trend-driven capital, respectively. Ekko's Q3 2026 founder data shows current idea submissions concentrated in AI & ML rather than these historically high-failure sectors — but 71.4% of those ideas still score in the weakest viability band, proving sector choice isn't what determines survival. Unvalidated customer and monetization assumptions are.
Which Sectors Account for the Most Startup Failures?
CB Insights' analysis of 431 VC-backed shutdowns since 2023 shows failure concentrated in three sectors, together accounting for roughly 40% of all failures:
- Healthcare & biotech: 14.4% (62 companies)
- Fintech: 13.2% (57 companies)
- Food & agriculture: 12.5% (54 companies)
Media & entertainment and retail & e-commerce tie at 10.2%, followed by blockchain (7.7%), enterprise software (6.7%), transportation & logistics (5.3%), consumer products (4.6%), and climate & energy (4.2%).
Three Sectors, Three Different Failure Modes
Healthcare & biotech leads in capital destroyed too — $5.1B, the most of any sector — because more than half the category is biotech, and clinical-stage drug development is binary and capital-intensive by nature. Areteia Therapeutics raised $425M and shut down after its asthma therapeutic missed clinical trial expectations.
Fintech failures skew early and international: median equity funding of just $4M (vs. $11M dataset-wide), and 60% based outside the US, concentrated in the 2021–2022 emerging-market fintech boom. ZestMoney ($114M) and Ula ($141M) both raised at the peak and struggled with unit economics once capital tightened.
Food & agriculture is the surprise entrant — roughly a third of its failures are alt-protein or cultivated meat startups like Believer Meats ($390M) and Motif FoodWorks ($344M), reflecting a broader unwind of a trend-driven capital wave.
| Sector | Failure driver | Signature risk |
|---|---|---|
| Healthcare & biotech | Clinical/scientific risk | Binary, capital-intensive, priced in from the start |
| Fintech | Funding-environment risk | Early-stage, boom-bust cycles, thin unit economics |
| Food & agriculture | Trend/timing risk | Capital chasing a category ahead of real demand |
Where Today's Founders Are Actually Building — Ekko's Q3 2026 Data
CB Insights' sector breakdown tells you where startups have already failed. Ekko's Q3 2026 Venture Benchmark — drawn from real founder idea submissions on the Ekko validation platform — shows where the next cohort is heading, and the mismatch is worth noting.
Founder interest this quarter split almost evenly between "Other" (45.9%) and AI & ML (43.2%), with B2B SaaS trailing at just 10.8%. None of CB Insights' three highest-failure sectors — healthcare & biotech, fintech, food & ag — show up as a dominant category in current founder intent. That's not necessarily reassuring: it suggests founders are chasing AI hype broadly rather than converging on a specific, validated vertical, which is its own version of the "wrong timing" risk that sank the food & ag and blockchain cohorts in the CB Insights dataset.
The Viability Gap Ekko Is Built to Catch
More telling is Ekko's viability data on the ideas actually entering the pipeline: 71.4% scored in the bottom viability band (0–50), and 73% of founders submitted ideas with vague target customer definitions. Whatever sector a founder chooses, if the customer isn't defined and the monetization path isn't clear — true for 100% of validated ideas in the quarter — that idea is carrying the same structural risk that shows up in CB Insights' shutdown data, regardless of which sector label it eventually gets filed under.
What This Means for Founders and Investors
Sector alone doesn't predict failure — the risk profile within the sector does. A biotech bet lives or dies on trial data; a fintech bet on whether unit economics survive once cheap capital disappears; an AI startup today (where founder attention is concentrated per Ekko's data) on whether it's solving a defined problem for a defined customer or riding hype toward the same fate as 2021's alt-protein and NFT waves.
The practical move is to test that risk before committing capital or building time to it — which is the gap Ekko is built to close: a real landing page and waitlist, a customer-clarity check, and a pre-mortem, before a founder finds out the hard way which failure mode their idea was carrying.
Key Takeaways
- Healthcare & biotech, fintech, and food & agriculture account for ~40% of the 431 VC-backed failures CB Insights tracked, each failing for a structurally different reason.
- Healthcare & biotech destroyed the most capital ($5.1B) due to binary clinical risk; fintech skews early-stage and international; food & ag's failures are largely alt-protein hype unwinding.
- Ekko's Q3 2026 data shows founder attention concentrated in AI & ML (43.2%) and "Other" (45.9%), not in CB Insights' highest-failure sectors — but 71.4% of submitted ideas still scored in the weakest viability band.
- Sector doesn't predict failure on its own; unvalidated customer and monetization assumptions do — and those are visible before a company is even built.
Frequently asked
Questions, answered.
Which industries have the highest startup failure rate? Healthcare & biotech (14.4%), fintech (13.2%), and food & agriculture (12.5%) lead CB Insights' analysis of 431 VC-backed shutdowns, together accounting for roughly 40% of all failures tracked.
Why do healthcare and biotech startups fail so often? More than half of failed healthcare & biotech companies are biotech specifically, where clinical-stage drug development is capital-intensive and binary — a treatment either works in trials or it doesn't. Healthcare & biotech destroyed the most capital of any sector at $5.1B, exemplified by Areteia Therapeutics' $425M shutdown after a failed asthma trial.
Is fintech failure different from healthcare failure? Yes. Fintech failures skew much earlier-stage (median $4M raised vs. $11M dataset-wide) and more international (60% based outside the US), concentrated in the 2021–2022 emerging-market fintech funding boom. It's a funding-cycle and unit-economics problem, not a clinical-risk problem.
Does choosing a "safer" sector reduce a startup's chance of failure? Not on its own. Ekko's Q3 2026 founder data shows current idea submissions are concentrated in AI & ML and away from the historically high-failure sectors — yet 71.4% of those ideas still scored in the bottom viability band, because the underlying customer and monetization assumptions were never validated. Sector selection doesn't substitute for validating demand before building.
Sources: CB Insights, "Startup Failure: The Top Reasons Why Startups Fail"; Ekko, "Q3 2026 Venture Benchmark: Why 100% of Founders Fail Pre-Build."